At 9.40 AM on Thursday, Thyrocare Technologies share price rose by 14.69% and was trading at ₹882.20. The company has reported a healthy 21.9% rise in its net profit for the quarter ending March 2025.
The company’s profit stood at ₹21.7 crore, up from ₹17.8 crore in the same quarter last year. This growth came mainly from improved operations and a steady increase in the number of diagnostic tests performed.
Revenue also went up by 21.3% during the quarter, reaching ₹187.2 crore compared to ₹154.3 crore in Q4 of FY24. The company’s EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) grew even more sharply—by 70.5%—to ₹57.8 crore.
Thanks to this, the EBITDA margin improved from 22% last year to 30.9% this year. This indicates that Thyrocare has been able to control costs better and work more efficiently.
The Board of Directors has proposed a final dividend of ₹21 per equity share for FY25. This proposal will need to be approved by shareholders in the upcoming meeting.
Thyrocare, based in Navi Mumbai, runs a large chain of diagnostic and preventive health labs across India. The company has been working on expanding its range of tests and improving its digital services. These efforts have helped increase the number of tests done, which in turn led to better revenue.
Before the earnings were announced, shares of Thyrocare closed 3.2% lower at ₹769 on the Bombay Stock Exchange (BSE), showing that investors were cautious. However, on April 24 at 9:30 AM IST, the share price had risen sharply to ₹853.95—an increase of ₹84.75 or 11.02%.
Thyrocare’s Q4 performance shows strong growth, with better profits, higher revenues, and improved efficiency. With a proposed dividend and clear signs of business expansion, the company looks well-positioned for the future.
Read more on: Dalmia Bharat Shars Rose ~3% After Release of Q4FY25 Earnings
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Apr 24, 2025, 9:58 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
